Back to results
US 12,594,244 B2Granted
Therapeutic compositions for treatment of human immunodeficiency virus
AssigneeGilead Sciences, Inc.
InventorsBenjamin Micah Collman, Lei Hong, Joanna M. Koziara
Life of this patent
Estimating the term…
Abstract
A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
Claims29
A tablet comprising from 6.5-11.0% w/w of a compound of Formula I:
- or a pharmaceutically acceptable salt thereof, 3.0-4.5% w/w tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and 25-30% w/w emtricitabine or a pharmaceutically acceptable salt thereof, where the weight percentages denote a proportion of the whole tablet.
A tablet comprising from 7.0-11.0% w/w of a compound of Formula II:
- 3.5-4.1% w/w tenofovir alafenamide hemifumarate, and 25-30% w/w emtricitabine, where the weight percentages denote a proportion of the whole tablet.
A tablet comprising:
- (i) from about 6.4 w/w to about 8.5% w/w of a compound of Formula II
- (ii) about 25% w/w to about 32% w/w emtricitabine,
- (iii) about 3.5% w/w to about 4.5% w/w tenofovir alafenamide hemifumarate,
- (iv) about 46% w/w to about 57% w/w microcrystalline cellulose,
- (v) about 5.9% w/w to about 8.5% w/w croscarmellose sodium, and
- (vi) about 1.0-2.0% w/w magnesium stearate.
3 more elements
A method of therapeutic treatment of an HIV infection comprising administering to a subject a tablet comprising:
- (i) from about 6.4 w/w to about 8.5% w/w of the compound of Formula II
- (ii) about 25% w/w to about 32% w/w emtricitabine,
- (iii) about 3.5% w/w to about 4.5% w/w tenofovir alafenamide hemifumarate,
- (iv) about 46% w/w to about 57% w/w microcrystalline cellulose,
- (v) about 5.9% w/w to about 8.5% w/w croscarmellose sodium, and
- (vi) about 1.0-2.0% w/w magnesium stearate.
3 more elements
Dependencies are inferred from the claim text.